Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 10 hours ago

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 27, 2026

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 26, 2026

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 20, 2026

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use.

PRNewsWire • Oct 16, 2026

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

Business Wire • Oct 12, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Zacks Investment Research • Oct 9, 2026

Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years

I analyze 84 top Ten-Year tenured dividend dogs, focusing on yield-based selection and free cash flow safety for October 2026. Chimera Investment, Mach Natural Resources, and Matthews International lead projected net gains, with average estimated returns of 48.6% on $10k invested. Fifteen of thirty-six 'safer' dividend dogs meet the IDEAL standard, with annual dividends from $1k invested exceeding their share price.

Seeking Alpha • Oct 9, 2026

Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion

Viatris said on Thursday ‌it will buy Pacira Biosciences for $1.65 billion, adding the ​pain therapy maker's ​products to its portfolio.

Reuters • Oct 8, 2026

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

Investors Business Daily • Oct 8, 2026